Clarigard® and Polygard® clarification prefilters remove particulates at different steps in biopharma production. These polypropylene filters are offered in both capsule and cartridge formats, with multiple sizes to fit different application needs.
Clarigard® filters have a 99.99% particle retention rating, protect downstream operations, and offer low extractables and broad chemical compatibility.
Polygard® filters provide high dirt-holding capacity with minimal differential pressure. These nominally rated filters can be used for particulate removal from liquids and gases in multiple applications.
Pre-configured to meet all your biopharmaceutical process and filtration needs, our Series 4000™ line of single-round stainless steel filter housings offers a variety of T-Line and In-Line designs, as well as a wide range of tube sizes.
Our flexible hardware and systems for disposable depth filters are ideal for clarification at pilot and process scales, featuring the modular Pod device that enables scale-up and scale-down within the same footprint.
The ekko™ Acoustic Cell Processing System is an automated, modular cell processing platform that includes an interface with a user-friendly protocol builder, and single-use consumables for closed-system processing.
To prepare your cell culture harvest for downstream chromatography and purification, our Millistak+® and Clarisolve® depth filters and flocculation polymers offer upstream process solutions for both primary and secondary clarification. Millistak+® HC and HC Pro can be used as polishing filters at a certain point in the downstream purification process.
Monoclonal antibody manufacturing is a highly templated approach used to produce mAb-based immunotherapies. Robust, scalable process solutions are required at every step to ensure high therapeutic concentration and process safety, while meeting speed-to-market and cost containment concerns.
Growing use of gene therapies is driving rapid innovation in an evolving global market. Manufacturers bringing new gene therapies to life face complex challenges, requiring an experienced partner capable of integrating vector manufacturing, testing, safety, process development, and regulatory compliance.
Antibody-drug conjugation (ADC) technology uses monoclonal antibodies (mAbs) to deliver potent, highly active pharmaceutical ingredients (HPAPIs) to targeted cells. Learn about processes and areas of expertise required to advance your ADC to market.
Consistent, reliable performance is key to blood plasma fractionation, posing challenges to improve yield, maintain process economics, and manage regulatory requirements. Learn how the right partner can help fractionators to better serve patients globally with enhanced IgG, albumin, and Factor VIII products.
Manufacturing the final dosage form of a small molecule drug requires robust quality and design in development of the formulation and production of the final product. Explore solutions and best practices to advance and accelerate small molecule pharmaceuticals, from development to commercialization.
M Lab™ Collaboration Centers offer in-person or virtual visits with experts to solve the challenges in your biopharma and pharma facilities. From upstream to downstream and through the final fill, our non-GMP facilities are resource hubs where you can explore, learn, and collaborate.